February 2007 Oncology News International

News
Article

Cover Story

  • Pancreatic Ca Vaccine Extends Survival After Surgery

Focus on Lung Cancer

  • BB-10901 Compound Delivers Potent Agent to CD56+ Tumors
  • First-line Nab-paclitaxel Shows Efficacy in NSCLC Trials

Focus on Hematology

  • High Response Rate for Lenalidomide Plus Melphalan and Prednisone in Newly Diagnosed Multiple Myeloma Patients

Cancer Care & Economics

  • Billing Plans for Routine Care Essential When Patients Enroll in Clinical Trials
  • RHIOs Allow Exchange of Electronic Info

Recent Videos
4 experts in this video
7 experts are featured in this series.
2 KOLs are featured in this series.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
2 experts are featured in this series.
2 experts are featured in this series.
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
Related Content
The PSA response rate and radiographic PFS were similar with the 177Lu-based combination regimen vs the radiotracer alone in metastatic CRPC.

177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC

Roman Fabbricatore
October 30th 2025
Article

The PSA response rate and radiographic PFS were similar with the 177Lu-based combination regimen vs the radiotracer alone in metastatic CRPC.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Site Logo

Career Stage and Location Found to Impact Oncology Coverage in the US

Ariana Pelosci
October 30th 2025
Article

Rural populations and those with higher cancer burden and socioeconomic risk were found to have gaps in oncology care across the US.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Data from the phase 1/2 GOBLET trial show an objective response rate that exceeds a historical benchmark for second-line squamous cell anal carcinoma care.

Pelareorep Combo Yields Responses in Squamous Cell Anal Carcinoma

Russ Conroy
October 29th 2025
Article

Data from the phase 1/2 GOBLET trial show an objective response rate that exceeds a historical benchmark for second-line squamous cell anal carcinoma care.

What is the Impact of the SHARON Trial on Pancreatic Cancer Research?

What is the Impact of the SHARON Trial on Pancreatic Cancer Research?

Ariana Pelosci
October 29th 2025
Article

Kenneth H. Yu, MD, discusses the results from the SHARON trial in pancreatic cancer that were presented at ESMO 2025.